Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Rapcabtagene autoleucel single agent · 1 trial · 5 indications
CRR defined as best overall response (BOR) of CR after rapcabtagene autoleucel infusion as per Lugano criteria for 3L+ Diffuse Large B-Cell Lymphoma (DLBCL) and 1L High Risk Large B-Cell (HR LBCL)
| Arm | Type | Description |
|---|---|---|
| CLL/SLL | EXPERIMENTAL | Dose escalation of rapcabtagene autoleucel in combination with ibrutinib |
| 3L+ DLBCL | EXPERIMENTAL | Dose escalation and expansion of rapcabtagene autoleucel single agent in 3L+ DLBCL |
| Adult ALL | EXPERIMENTAL | Dose escalation of rapcabtagene autoleucel single agent in adult ALL |
| 1L HR LBCL | EXPERIMENTAL | Rapcabtagene autoleucel single agent in 1L HR LBCL |
| Name | Type | Description |
|---|---|---|
| Rapcabtagene autoleucel single agent | BIOLOGICAL | Single infusion of rapcabtagene autoleucel |
| Ibrutinib | DRUG | Tablets or capsules for oral daily use |
Inclusion Criteria: * ECOG performance status 0-1 for ALL and DLBCL * ECOG performance status 0-2 for 1L HR LBCL at screening * CLL or SLL diagnosis according to iwCLL criteria * CLL/SLL in SD or PR after at least 6 months of ibrutinib, either as second or subsequent line of therapy * DLBCL diagnos...
Rapcabtagene autoleucel is an investigational cell therapy being studied for the treatment of chronic lymphocytic leukemia (CLL). It is also being evaluated in other blood cancers, including small lymphocytic lymphoma, diffuse large B-cell lymphoma, acute lymphoblastic leukemia, and large B-cell lymphoma, as part of an ongoing clinical trial.
Rapcabtagene autoleucel is being developed by Novartis AG, a global healthcare company. Novartis is listed on the stock exchange under the ticker symbol NVS. The drug is currently in Phase 1 clinical development for chronic lymphocytic leukemia and other hematologic malignancies.
Rapcabtagene autoleucel is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1/II study is currently active but not recruiting participants, and it is being conducted across multiple countries.
Rapcabtagene autoleucel is being studied in a Phase 1/II clinical trial with the identifier NCT03960840. This trial is evaluating the drug in patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, diffuse large B-cell lymphoma, acute lymphoblastic leukemia, and large B-cell lymphoma. The trial is active but not recruiting.
Rapcabtagene autoleucel is a cell therapy, as indicated by its '-cel' suffix, which denotes a cellular treatment. It is being developed as a single agent for chronic lymphocytic leukemia. The specific molecular target of this therapy has not been disclosed in the available information.
Rapcabtagene autoleucel is a distinct investigational cell therapy developed by Novartis. It is being studied specifically for chronic lymphocytic leukemia and other blood cancers. No alternative names for this drug have been reported, and it is not known to be identical to any other approved or investigational therapy.